By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its HRS-5635, an HBV-targeted siRNA drug, to be used in combination with Peg-IFNα for the treatment of chronic hepatitis B virus (HBV).
HRS-5635 Efficacy and Safety Profile
HRS-5635 exhibited excellent antiviral activity against all HBV genotypes in non-clinical efficacy studies, demonstrating efficient and long-lasting antiviral effects in vivo. Non-clinical safety evaluation studies showed that HRS-5635 had no off-target activity and demonstrated high safety.-Fineline Info & Tech